...
首页> 外文期刊>Applied Microbiology and Biotechnology >Differential effects of bioreactor process variables and purification on the human recombinant lysosomal enzyme beta-glucuronidase produced from Chinese hamster ovary cells
【24h】

Differential effects of bioreactor process variables and purification on the human recombinant lysosomal enzyme beta-glucuronidase produced from Chinese hamster ovary cells

机译:生物反应器工艺变量和纯化对来自中国仓鼠卵巢细胞产生的人重组溶酶体酶β-葡糖醛酸酶的差异

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

beta-Glucuronidase is a lysosomal enzyme and a molecular model of a class of therapeutics approved as enzyme replacement therapies for lysosomal storage diseases. Understanding the effect of bioreactor process variables on the production and quality of the biologics is critical for maintaining quality and efficacy of the biotherapeutics. Here, we have investigated the effect of three process variables, in a head-to-head comparison using a parallel bioreactor system (n = 8), namely 0.25 mM butyrate addition, a temperature shift (from 37 to 32 degrees C), and a pH shift (from 7.0 to 6.7) along with a control (pH 7, temperature 37 degrees C, and no additive) on the production and quality of human recombinant beta-glucuronidase (GUS) by a Chinese hamster ovary (CHO) cell line. The study was performed as two independent runs (2 bioreactors per treatment per run; n <= 4). Although statistically not significant, protein production slightly increased with either 0.25 mM butyrate addition (13%) or pH shift (7%), whereas temperature shift decreased production (12%, not significant). Further characterization of the purified GUS samples showed that purification selectively enriched the mannose-6-phosphate (M6P)-containing GUS protein. Noticeably, a variation observed for the critical quality attribute (CQA) of the enzyme, namely M6P content, decreased after purification, across treatment replicates and, more so, across different treatments. The dimer content in the purified samples was comparable (similar to 25%), and no significant discrepancy was observed in terms of GUS charge variants by capillary electrophoresis analysis. MALDI-TOF/TOF analysis of released N-glycans from GUS showed a minor variation in glycoforms among the treatment groups. Temperature shift resulted in a slightly increased sialylated glycan content (21.6%) when compared to control (15.5%). These results suggest that bioreactor processes have a differential effect, and better control is required for achiev
机译:β-葡萄糖醛酸酶是溶酶体酶和一类治疗剂的分子模型,被批准为溶酶体储存疾病的酶替代疗法。了解生物反应器过程变量对生物制剂的生产和质量的影响对于维持生物治疗方法的质量和功效至关重要。在这里,我们研究了三个过程变量的效果,使用平行生物反应器系统(n = 8),即0.25mm丁酸丁酸酯添加,温度偏移(从37〜32℃)的头部比较中的效果。 pH转移(从7.0至6.7)以及由中国仓鼠卵巢(CHO)细胞系的人重组β-葡糖醛酸酶(GUS)的生产和质量对照(pH7,温度37摄氏度和没有添加剂) 。该研究作为两个独立的运行进行(每次处理2个生物反应器; N <= 4)。虽然统计学上不显着,但蛋白质产生略微增加,丁酸酯加成0.25mm丁酸加成(13%)或pH转移(7%),而温度变化降低(12%,不显着)。纯化的GUS样品的进一步表征显示,纯化选择性地富集甘露糖-6-磷酸(M6P)含有GUS蛋白。明显地,对于酶的临界质量属性(CQA)观察到酶的临界质量属性(CQA)的变异,即在纯化后降低,在治疗后,在不同的处理中,更重要的是。纯化样品中的二聚体含量可比较(类似于25%),并且在Gus电泳变体方面没有观察到显着的差异,通过毛细管电泳分析。来自GUS释放的N-聚糖的MALDI-TOF / TOF分析显示治疗组中的糖族的微小变化。与对照相比(15.5%)相比,温度变化导致唾液酸化甘油含量略微增加(21.6%)。这些结果表明生物反应器过程具有差异效果,并且需要更好的控制

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号